Annual CFO
-$50.92 M
-$36.49 M-252.89%
31 December 2023
Summary:
Barinthus Biotherapeutics annual cash flow from operations is currently -$50.92 million, with the most recent change of -$36.49 million (-252.89%) on 31 December 2023. During the last 3 years, it has fallen by -$39.90 million (-361.78%). BRNS annual CFO is now -361.78% below its all-time high of -$11.03 million, reached on 01 December 2020.BRNS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$18.20 M
-$6.19 M-51.57%
30 September 2024
Summary:
Barinthus Biotherapeutics quarterly cash flow from operations is currently -$18.20 million, with the most recent change of -$6.19 million (-51.57%) on 30 September 2024. Over the past year, it has dropped by -$7.01 million (-62.61%). BRNS quarterly CFO is now -253.13% below its all-time high of $11.88 million, reached on 01 September 2022.BRNS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$61.63 M
-$7.01 M-12.83%
30 September 2024
Summary:
Barinthus Biotherapeutics TTM cash flow from operations is currently -$61.63 million, with the most recent change of -$7.01 million (-12.83%) on 30 September 2024. Over the past year, it has dropped by -$18.96 million (-44.45%). BRNS TTM CFO is now -1326.27% below its all-time high of -$4.32 million, reached on 01 March 2020.BRNS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BRNS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -252.9% | -62.6% | -44.5% |
| 3 y3 years | -361.8% | -128.3% | -89.1% |
| 5 y5 years | - | - | - |
BRNS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -361.8% | at low | -253.1% | +7.2% | -458.9% | at low |
| 5 y | 5 years | -361.8% | at low | -253.1% | +7.2% | -1326.3% | at low |
| alltime | all time | -361.8% | at low | -253.1% | +7.2% | -1326.3% | at low |
Barinthus Biotherapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$18.20 M(+51.6%) | -$61.63 M(+12.8%) |
| June 2024 | - | -$12.01 M(+1.6%) | -$54.62 M(-8.3%) |
| Mar 2024 | - | -$11.82 M(-39.7%) | -$59.57 M(+17.0%) |
| Dec 2023 | -$50.92 M(+252.9%) | -$19.60 M(+75.2%) | -$50.92 M(+19.4%) |
| Sept 2023 | - | -$11.19 M(-34.0%) | -$42.66 M(+117.8%) |
| June 2023 | - | -$16.96 M(+434.2%) | -$19.59 M(+77.7%) |
| Mar 2023 | - | -$3.17 M(-72.0%) | -$11.03 M(-23.6%) |
| Dec 2022 | -$14.43 M | -$11.34 M(-195.4%) | -$14.43 M(+30.5%) |
| Sept 2022 | - | $11.88 M(-241.6%) | -$11.06 M(-55.7%) |
| June 2022 | - | -$8.39 M(+27.6%) | -$24.96 M(-20.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$6.58 M(-17.5%) | -$31.19 M(-4.3%) |
| Dec 2021 | -$32.58 M(+195.5%) | - | - |
| Dec 2021 | - | -$7.97 M(+295.0%) | -$32.58 M(+10.4%) |
| Sept 2021 | - | -$2.02 M(-86.2%) | -$29.51 M(+4.1%) |
| June 2021 | - | -$14.62 M(+83.5%) | -$28.35 M(+93.2%) |
| Mar 2021 | - | -$7.97 M(+62.8%) | -$14.68 M(+33.1%) |
| Dec 2020 | -$11.03 M | -$4.90 M(+468.6%) | -$11.03 M(+79.8%) |
| Sept 2020 | - | -$861.00 K(-9.4%) | -$6.13 M(+16.3%) |
| June 2020 | - | -$950.00 K(-78.0%) | -$5.27 M(+22.0%) |
| Mar 2020 | - | -$4.32 M | -$4.32 M |
FAQ
- What is Barinthus Biotherapeutics annual cash flow from operations?
- What is the all time high annual CFO for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics annual CFO year-on-year change?
- What is Barinthus Biotherapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics quarterly CFO year-on-year change?
- What is Barinthus Biotherapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics TTM CFO year-on-year change?
What is Barinthus Biotherapeutics annual cash flow from operations?
The current annual CFO of BRNS is -$50.92 M
What is the all time high annual CFO for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high annual cash flow from operations is -$11.03 M
What is Barinthus Biotherapeutics annual CFO year-on-year change?
Over the past year, BRNS annual cash flow from operations has changed by -$36.49 M (-252.89%)
What is Barinthus Biotherapeutics quarterly cash flow from operations?
The current quarterly CFO of BRNS is -$18.20 M
What is the all time high quarterly CFO for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high quarterly cash flow from operations is $11.88 M
What is Barinthus Biotherapeutics quarterly CFO year-on-year change?
Over the past year, BRNS quarterly cash flow from operations has changed by -$7.01 M (-62.61%)
What is Barinthus Biotherapeutics TTM cash flow from operations?
The current TTM CFO of BRNS is -$61.63 M
What is the all time high TTM CFO for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high TTM cash flow from operations is -$4.32 M
What is Barinthus Biotherapeutics TTM CFO year-on-year change?
Over the past year, BRNS TTM cash flow from operations has changed by -$18.96 M (-44.45%)